At UHN, we strive to deliver Compassionate Care & Caring. Learn more about the services and supports that are available to you throughout your journey.
Our UHN programs and services are among the most advanced in the world. We have grouped our physicians,
staff, services and resources into 10 medical programs to meet the needs of our patients and help us make
the most of our resources.
At the heart of everything we do at UHN are our Healthcare Professionals. Refer a patient to one of our 12 medical programs. Learn more about the resources and opportunities available for professional growth.
University Health Network has grown to be one of the largest research and teaching hospital networks in Canada - pioneers in improving the lives of patients. Our long history of health professions education at Toronto General, Toronto Western, Princess Margaret and Toronto Rehab hospitals has consistently advanced the science of education.
University Health Network is a health care and medical research organization in
Toronto, Ontario, Canada. The scope of research and complexity of cases at UHN has made us a national and international
source for discovery, education and patient care.
Being touched by illness affects us in different ways. Many people want to give back to the community
and help others. At UHN, we welcome your contribution and offer different ways you can help so you can find one that suits you.
The Newsroom is the source for media looking for information about UHN or trying to connect with one
of our experts for an interview. It's also the place to find UHN media policies and catch up on our news stories, videos, media releases,
podcasts and more.
A pilot study led by researchers at UHN could redefine the treatment trajectory for those affected by COVID-19–induced severe acute respiratory distress syndrome (ARDS).
ARDS, a severe inflammatory disease of the lungs, can develop in patients with COVID-19 if the virus enters the lower respiratory tract and damages the lungs. It is associated with a high mortality rate.
Specific cells from the placenta called decidual stromal cells (DSCs) have shown promise in treating other acute inflammatory conditions and evidence suggests they could benefit patients with COVID-19-induced ARDS.
To explore this potential treatment, a clinical trial was conducted across three hospitals in Ontario between December 2020 and June 2021. In this study, researchers administered placental DSCs to a cohort of 19 adult patients affected by COVID-19-induced ARDS and conducted a comprehensive observation of the patient's responses to the placental DSC treatment.
"We found that DSC infusions were associated with an impressive 84.2 per cent survival rate, suggesting that these infusions are effective at treating," says
Dr. John Granton, clinician investigator at the Toronto General Hospital Research Institute (TGHRI).
This study not only highlights the safety of DSC therapy but also its efficacy. The promising results were further underscored by the fact this novel therapy could offer a lifeline to individuals across age groups.
"This trial supports the further evaluation of DSCs with a larger, randomized, controlled trial that will comprehensively evaluate the safety profile and efficacy of DSC in severe ARDS," says Dr. Igor Novitzky Basso, clinician investigator at Princess Margaret Cancer Centre.
Dr. Jonas Mattsson, Director of UHN's Hans Messner Allogeneic Transplant Program and a clinician investigator at Princess Margaret Cancer Centre, adds: "Thanks to the generous support of our donors like Ajay Virmani and the Cargojet Foundation, we can conduct these innovative pilot studies to generate the evidence we need to carry out larger clinical trials.
"This study marks a critical milestone in the fight against severe COVID-19, offering a glimmer of hope for those navigating the dynamic landscape of respiratory complications."
This work was supported by generous donations from UHN Foundation, The Princess Margaret Cancer Foundation and the Cargojet Foundation.